| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be8e0da1b314bf83e52dfe44a1e14f12 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-165
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2469-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56983 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate |
2020-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9015a1b1a0f43563a5e635541040f7ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32b01106a096c5393e98c9f2579c65e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c72b62de45e2619475ed525874a4982a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d12765e06b7c0d249c10e3e31fd86942
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ab2b482cbd3b2bba845d0c227c6a10d4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20409e1425a94d1bb44f91e80e36b0a4 |
| publicationDate |
2021-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11053304-B1 |
| titleOfInvention |
Anti-SARS-Cov-2 antibodies derived from 6nb6 |
| abstract |
This disclosure provides antibodies and antigen-binding fragments that are derived from 6nb6 and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments herein can be used to diagnose a SARS CoV 2 infection. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11345741-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022227844-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11634477-B2 |
| priorityDate |
2020-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |